— Study Showed 96.4% Sensitivity for T2Candida Panel Compared to 60% in Blood Culture in Review of 55 Candida Cases —
LEXINGTON, Mass., Sept. 16, 2015 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (Nasdaq:TTOO), a company developing innovative diagnostic products to improve patient health, today announced that results from a data analysis of the company’s T2Candida® Panel for the detection and monitoring of Candida infection and sepsis were published in Future Microbiology. The publication compared aggregated results from T2Candida in the detection of invasive candidiasis and candidemia to blood culture, which included samples acquired from more than 1,900 patients. Out of 55 total cases, T2Candida demonstrated a 96.4 percent sensitivity (53 cases) compared to 60 percent (33 cases) with blood culture.
“These data, from a robust set of studies that include a large number of infected patients, further demonstrate T2Candida’s ability to rapidly detect, identify, and monitor Candida direct from whole blood much more accurately and faster than all other diagnostic approaches, which require blood culture,” said John McDonough, president and CEO of T2 Biosystems. “We are very pleased with the strong clinical validation this analysis shows, and we are hopeful that T2Candida will continue to make an important difference in helping to improve outcomes for sepsis patients through early and accurate diagnosis.”
The Future Microbiology paper was published today online at http://bit.ly/1Kg20J4 and will appear in an upcoming print edition of the journal.
About The T2Candida Panel
The T2Candida Panel is the first sepsis pathogen diagnostic that provides species-specific results in three to five hours without the need for blood culture, which can take up to six days to provide a result. The rapid detection of Candida enables physicians to provide targeted treatment quickly, and research has shown this can reduce the length of stay in the hospital of a patient with Candida sepsis by almost nine days at a cost savings of approximately $26,887. A rapid negative result can prevent unnecessary administration of antimicrobials, further reducing costs. In addition, a rapid negative result can prevent or reduce antimicrobial resistance, which the Centers for Disease Control and Prevention has designated a serious threat.
Sepsis is one of the leading causes of death in the United States and the most expensive hospital-treated condition, with costs to the healthcare system exceeding $20 billion each year, according to the U.S. Department of Health and Human Services. T2Candida® uses magnetic resonance technology to help detect the presence of five clinically relevant species of Candida, the most lethal form of common blood stream infections that cause sepsis, directly from a patient’s blood sample in three to five hours, versus up to six days or more with current diagnostic methods. Studies have shown that if Candida can be diagnosed and treated with targeted therapy beginning within 12 hours of the presentation of symptoms, the associated mortality rate can be reduced from approximately 40 percent to 11 percent.
Candidemia is a systemic fungal infection that occurs when Candida organisms in the blood spread to organs and tissues throughout the body. Candidemia is the fourth leading hospital-acquired bloodstream infection and the most lethal form of common bloodstream infection that causes sepsis, according to the Center for Disease Control (CDC), with an approximate 40 percent mortality rate. In the absence of a rapid, accurate diagnostic, appropriate therapeutic intervention for candidemia is often delayed, resulting in a mortality rate that is three to four times higher than when early, targeted therapy is initiated. According to a study published in Antimicrobial Agents and Chemotherapy, the mortality rate can be reduced to 11 percent with the initiation of targeted therapy within 12 hours of presentation of symptoms. On average, candidemic patients require 40 days of hospitalization and have a hospital cost of $130,000.
About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the performance of the Company’s diagnostic products and the ability to bring such products to market. These and other important factors discussed under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 4, 2015, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
CONTACT: Media Contact: Susan Heins, Pure Communications email@example.com 864.286.9597 Investor Contact: Matt Clawson, Pure Communications firstname.lastname@example.org 949-370-8500